Closing the Gap for High-Risk Myeloma Patients at Diagnosis

What Longer MM Survival Means for Quality of Life and Side Effects

Weighing Early, Small-Sample MM Data in Real-World Patient Decisions

Tailoring Neurological Monitoring to Myeloma Risk Factors

Rethinking Intrathecal Chemotherapy for CNS Myeloma

Why CAR-T and Bispecifics May Outperform Older Therapies in CNS Myeloma

Understanding the Poor Prognosis of CNS Myeloma

What Myeloma's Immune Therapy Progress Means for Related Plasma Cell Disorders

Patient Selection Amid Transplant, CAR-T, and Bispecifics

Positioning Transplant in the Era of CAR-T and Bispecifics